Abstract
The currently available drugs for long-term treatment of obesity are sibutramine and orlistat. They have been shown to be able to induce significant weight loss, with important co-morbidity reduction, allowing the maintenance of reduced body weight for at least 1-2 years. Cardiostimulating and gastrointestinal adverse effects are however not negligible.
Keywords: Pharmacotherapy, sibutramine, orlistat, body weight, fat, energy balance, physical activity, diet
Mini-Reviews in Medicinal Chemistry
Title: Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat
Volume: 7 Issue: 1
Author(s): J.-P. Chaput, S. St-Pierre and A. Tremblay
Affiliation:
Keywords: Pharmacotherapy, sibutramine, orlistat, body weight, fat, energy balance, physical activity, diet
Abstract: The currently available drugs for long-term treatment of obesity are sibutramine and orlistat. They have been shown to be able to induce significant weight loss, with important co-morbidity reduction, allowing the maintenance of reduced body weight for at least 1-2 years. Cardiostimulating and gastrointestinal adverse effects are however not negligible.
Export Options
About this article
Cite this article as:
Chaput J.-P., St-Pierre S. and Tremblay A., Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat, Mini-Reviews in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/138955707779317849
DOI https://dx.doi.org/10.2174/138955707779317849 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk
Current Pharmaceutical Design Resveratrol and Cardiovascular Disease
Current Nutrition & Food Science Determinants of 25-Hydroxyvitamin D Concentrations in Infants and Toddlers
Current Nutrition & Food Science Isolated Systolic Hypertension: Epidemiology, Pathogenesis and Treatment
Current Hypertension Reviews Carotid Ultrasound in One, Two and Three Dimensions
Vascular Disease Prevention (Discontinued) Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Editorial [Hot Topic Cells, Micro- and Nanosystems in Reconstructive Medicine: Past, Present, and Future Guest Editors: Christian Andressen & Andreas Wree]
Current Pharmaceutical Biotechnology Thioredoxin-1 is a Novel and Attractive Therapeutic Approach for Various Diseases Including Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Integrin (αvβ3) Targeted RGD Peptide Based Probe for Cancer Optical Imaging
Current Protein & Peptide Science Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Drug Targets for Obesity and Depression: From Serotonin to Leptin
Current Drug Targets